A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Pexidartinib (Primary)
- Indications Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
- Focus Registrational; Therapeutic Use
- Acronyms ENLIVEN
- Sponsors Daiichi Sankyo Inc
- 13 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 13 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 07 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.